Total submissions: 4
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Baylor Genetics | RCV000707047 | SCV001524575 | uncertain significance | Familial dysautonomia | 2019-11-20 | criteria provided, single submitter | clinical testing | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. |
| Labcorp Genetics |
RCV001345125 | SCV001539226 | uncertain significance | not provided | 2018-04-18 | criteria provided, single submitter | clinical testing | This sequence change replaces valine with isoleucine at codon 92 of the IKBKAP protein (p.Val92Ile). The valine residue is moderately conserved and there is a small physicochemical difference between valine and isoleucine. This variant is present in population databases (rs757852635, ExAC 0.006%). This variant has not been reported in the literature in individuals with IKBKAP-related disease. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: Tolerated; PolyPhen-2: Benign; Align-GVGD: Class C0. The isoleucine amino acid residue is found in multiple mammalian species, suggesting that this missense change does not adversely affect protein function. These predictions have not been confirmed by published functional studies and their clinical significance is uncertain. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Fulgent Genetics, |
RCV002499278 | SCV002790070 | uncertain significance | Medulloblastoma; Familial dysautonomia | 2022-05-31 | criteria provided, single submitter | clinical testing | |
| Natera, |
RCV000707047 | SCV001463100 | uncertain significance | Familial dysautonomia | 2020-09-16 | no assertion criteria provided | clinical testing |